Bonn Britta, Svanberg Petter, Janefeldt Annika, Hultman Ia, Grime Ken
RIA iMED DMPK (B.B., P.S., K.G.), CVMD iMED DMPK (A.J.), Drug Safety and Metabolism (I.H.), AstraZeneca R&D, Gothenburg, Sweden
RIA iMED DMPK (B.B., P.S., K.G.), CVMD iMED DMPK (A.J.), Drug Safety and Metabolism (I.H.), AstraZeneca R&D, Gothenburg, Sweden.
Drug Metab Dispos. 2016 Apr;44(4):527-33. doi: 10.1124/dmd.115.067769. Epub 2016 Feb 5.
A key requirement in drug discovery is to accurately define intrinsic clearance (CL(int)) values of less than 1 µl/min/10(6) hepatocytes, which requires assays that allow for longer incubation time as a complement to suspended hepatocytes. This study assessed the effectiveness of plated HepaRG cells, plated primary human hepatocytes (PHHs), and the HµREL human hepatocyte/stromal cell co-cultures for determination of low CL(int) values. The investigation demonstrated that the systems were capable of providing statistically significant CL(int) estimations down to 0.2 µl/min/10(6) cells. The HµREL assay provided a higher level of reproducibility, with repeat significant CL(int) values being defined in a minimum of triplicate consecutive assays for six of seven of the low CL(int) compounds compared with four of seven for PHHs and two of seven for HepaRG. The assays were also compared with a suspension assay using drugs with higher CL(int) values and diverse enzymology. The CL(int) values from the PHH and HµREL assays were similar to those defined by a hepatocyte suspension assay, indicating that they can be used interchangeably alongside a standard assay. Finally, data from these two assays could also predict in vivo hepatic metabolic CL(int) to within 3-fold for greater than 70% of the compounds tested, with average fold errors (AFE) of 1.6 and 2.3, respectively, whereas the HepaRG data were predictive to within 3-fold for only 50% of compounds (AFE 2.9). In summary, all systems have utility for low CL(int) determination, but the HµREL co-culture appears slightly superior regarding overall assay performance.
药物研发中的一个关键要求是准确界定内在清除率(CL(int))值低于1微升/分钟/10⁶个肝细胞,这需要能够延长孵育时间的检测方法,作为悬浮肝细胞检测方法的补充。本研究评估了贴壁培养的HepaRG细胞、贴壁培养的原代人肝细胞(PHH)以及HµREL人肝细胞/基质细胞共培养体系用于测定低CL(int)值的有效性。研究表明,这些体系能够提供低至0.2微升/分钟/10⁶个细胞的具有统计学意义的CL(int)估计值。HµREL检测方法具有更高的重现性,对于七种低CL(int)化合物中的六种,在至少连续三次重复检测中都能确定具有显著意义的CL(int)值,相比之下,PHH为七种中的四种,HepaRG为七种中的两种。还将这些检测方法与使用具有较高CL(int)值和不同酶学性质药物的悬浮检测方法进行了比较。PHH和HµREL检测方法得到的CL(int)值与肝细胞悬浮检测方法确定的值相似,表明它们可与标准检测方法互换使用。最后,对于超过70%的受试化合物,这两种检测方法的数据还能将体内肝脏代谢CL(int)预测在3倍以内,平均倍数误差(AFE)分别为1.6和2.3,而HepaRG数据仅能将50%的化合物预测在3倍以内(AFE 2.9)。总之,所有体系都可用于低CL(int)的测定,但就整体检测性能而言,HµREL共培养体系似乎略胜一筹。